Cargando…
Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules
This review, one in a series on myotonic dystrophy (DM), is focused on the development and potential use of small molecules as therapeutics for DM. The complex mechanisms and pathogenesis of DM are covered in the associated reviews. Here, we examine the various small molecule approaches taken to tar...
Autores principales: | Reddy, Kaalak, Jenquin, Jana R., Cleary, John D., Berglund, J. Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720693/ https://www.ncbi.nlm.nih.gov/pubmed/31426500 http://dx.doi.org/10.3390/ijms20164017 |
Ejemplares similares
-
Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
por: Jenquin, Jana R., et al.
Publicado: (2022) -
Quercetin selectively reduces expanded repeat RNA levels in models of myotonic dystrophy
por: Mishra, Subodh K., et al.
Publicado: (2023) -
Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1
por: López-Morató, Marta, et al.
Publicado: (2018) -
Modifications to toxic CUG RNAs induce structural stability, rescue mis-splicing in a myotonic dystrophy cell model and reduce toxicity in a myotonic dystrophy zebrafish model
por: deLorimier, Elaine, et al.
Publicado: (2014) -
Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy
por: Nakamori, Masayuki, et al.
Publicado: (2015)